<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03418155</url>
  </required_header>
  <id_info>
    <org_study_id>BH_2016001</org_study_id>
    <nct_id>NCT03418155</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of TongBi Capsule in Patients With Knee Osteoarthritis</brief_title>
  <official_title>Efficacy and Safety of TongBi Capsule in Patients With Knee Osteoarthritis:a Randomized, Double-blind, Placebo-controlled Post - Market Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and safety of TongBi capsule compared with placebo in the
      treatment of knee osteoarthritis in adults.Half of participants will receive TongBi capsule
      in combination,while the other half will receive a Placebo.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change from Baseline to week 4 in Visual Analog Scale (VAS)score</measure>
    <time_frame>0 weeks,2 weeks，4 weeks</time_frame>
    <description>VAS scores ranges from 0 to 100, with higher scores indicating heavier pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change from Baseline to week 4 in Western Ontarioand McMaster Universities</measure>
    <time_frame>0 weeks,2 weeks and 4 weeks</time_frame>
    <description>WOMAC scores ranges from 0 to 96, with higher scores indicating greater disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline to week 4 in The Short Form-36 Health Survey (SF-36) scores</measure>
    <time_frame>0 weeks,4 weeks</time_frame>
    <description>SF-36 scores ranges from 0 to 100,it shows the extent of physical function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of adverse events</measure>
    <time_frame>4 weeks</time_frame>
    <description>The number of adverse events related to treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Treatment of TongBi Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment of TongBi Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment of TongBi Capsule</intervention_name>
    <description>TongBi Capsule:0.31g,3times a day, oral, for 4 weeks.</description>
    <arm_group_label>Treatment of TongBi Capsule</arm_group_label>
    <other_name>capsule A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment of TongBi placebo</intervention_name>
    <description>TongBi placebo:0.31g,3times a day, oral, for 4 weeks.</description>
    <arm_group_label>Treatment of TongBi Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.45-75 years of age (including 45 years and 75 years old), men and women are not limited.

        2. western medicine diagnosis of knee osteoarthritis, clinical classification for primary.

        3.The severity of the imaging classification of K-L≤Ⅲ; 4. treatment VAS pain scores than
        40mm (select the subjects most obvious limb pain symptoms).

        5. informed consent form signed by the patient or legal representative.

        Exclusion Criteria:

          1. within 3 months prior to the trial, the patients were treated within intra-articular
             treatment.

          2. 4 weeks before the treatment, corticosteroids, non steroidal drugs, intra-articular
             injections or other drugs to improve the condition (such as cartilage protective
             agents) were used.

          3. The screening period has any disease history or evidence:

             The basic of serious cardiovascular and cerebrovascular diseases; An active, recurrent
             peptic ulcer or other hemorrhagic disease risk; Sales and other serious diseases of
             digestive system; An associated with malignant tumors, blood, or other serious
             diseases or system; Patients who are unable to cooperate or cooperate with other
             mental disorders.

          4. Before the screening, any laboratory test indicators meet the following standards:

             An admission of liver and kidney function showed that ALT and AST is more than 1.5
             times the upper limit of the normal value, Cr is more than 1.2 times the upper limit
             of normal (Reference Research Center laboratory where the range of normal value); An
             other clinically significant laboratory abnormalities, and the researchers judged not
             into the group.

          5. Allergic constitution or allergic to TongBi capsul, excipients or similar ingredients;

          6. Professional athletes;

          7. doubt or indeed history of alcohol and drug abuse;

          8. participants who participated in other clinical trials within the first 3 months;

          9. the researchers believe that patients should not participate in this clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiang Quan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiang Quan</last_name>
    <phone>86-010-88001060</phone>
    <email>doctorjq@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2018</study_first_submitted>
  <study_first_submitted_qc>January 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2018</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Quan Jiang</investigator_full_name>
    <investigator_title>Director，Devision of Rheumatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

